{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:42:57Z","timestamp":1740163377302,"version":"3.37.3"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011112","name":"UCB US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01192-2","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T12:01:46Z","timestamp":1718798506000},"page":"1705-1708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epicensus: The Drive to Elevating the Standard of Care for Patients with Psoriasis"],"prefix":"10.1007","volume":"14","author":[{"given":"Simon Francis","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Lazaridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"1192_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13555-022-00846-3","volume":"13","author":"J Koren","year":"2023","unstructured":"Koren J, et al. Elevating the standard of care for patients with psoriasis: \u2018calls to action\u2019 from epicensus, a multistakeholder pan-European initiative. Dermatol Ther. 2023;13:245\u201368.","journal-title":"Dermatol Ther"},{"key":"1192_CR2","unstructured":"Digital Health. Digital Care Program, the first telemedicine solution for psoriasis. 2022. https:\/\/www.digitalworlditalia.it\/digitalhealth\/terapia\/telemedicina\/digital-care-program-telemedicina-per-la-psoriasi-152695. Accessed 05 Mar 2024"},{"issue":"6","key":"1192_CR3","first-page":"934","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A, et al. German S3-Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - Part 1: treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934\u2013150.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1192_CR4","unstructured":"Healthcare Denmark. Decentralised clinical trials in Denmark. 2022. https:\/\/healthcaredenmark.dk\/national-strongholds\/innovation\/decentralised-clinical-trials\/. Accessed 05 Mar 2024"},{"key":"1192_CR5","unstructured":"Psoriasis Action. Have you ever shared a car with strangers? 2023. https:\/\/accionpsoriasis.org\/enladireccioncorrecta\/. Accessed 05 Mar 2024."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01192-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01192-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T17:18:05Z","timestamp":1721495885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01192-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":5,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01192-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Simon Francis Thomsen has received research support from Janssen, LEO Pharma, Novartis and UCB; and has served on advisory boards for Almirall, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, UCB, Union Pharmaceuticals; and as a speaker for LEO Pharma, Novartis, Symphogen and UCB and has been the recipient of a travel grant to GUF and EADV from Novartis. Valeria Corazza has no other conflicts of interest to declare. Matthias Augustin has received consulting fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Hexal, Janssen, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, UCB Pharma and Xenoport. Elizabeth Lazaridou has received research grants to her department from AbbVie, Genesis Pharma, Janssen, LEO, Lilly, Novartis, Pfizer and UCB; honoraria for activities such as lectures\/presentations\/speaker bureaus from AbbVie, Genesis Pharma, Janssen, LEO, Lilly, Novartis and UCB; support for attending meetings and\/or travel from AbbVie, Janssen, LEO, Lilly and UCB; and has participated on a Data Safety Monitoring Board or Advisory Board for AbbVie, Genesis Pharma, Janssen, LEO, Lilly, Novartis, Pfizer and UCB. Llu\u00eds Puig has received grants\/support paid to his institution from AbbVie, Almirall, Amgen, Boehringer Ingelheim, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi and UCB; consulting fees from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB; and payment\/honoraria for activities such as lectures\/presentations\/speaker bureaus for Janssen, Lilly and Novartis. Lo\u00efc Guillevin has served as a consultant for Boehringer Ingelheim, Certara, ESAI, GSK, Lilly, Novartis, Novo Nordisk, Roche, Sanofi, UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}